Evaluation of Effectiveness of Dexamethazone versus Hydrocortisone in Reducing Hospital Length, Oxidative Stress Factors and Inflammatory Mediators in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Patients.

Comparing the effectiveness of hydrocortisone and dexamethasone on reducing clinical symptoms,laboratory data in patients with exacerbation of chronic obstructive pulmonary disease hospitalized in the internist department.

A clinical trial with two intervention groups, double-blind, randomized, on 70 patients with exacerbation of chronic obstructive pulmonary disease who were randomly divided into two groups of 35 by computer random generation.

Study place:Imam Sajjad Hospital,Yasuj. For patients with admission conditions,clinical and laboratory variables'll be measured and recorded, and standard treatment'll begin for all of them. After randomization, group 1 patients are given 8 mg of single-dose intravenous(IV) dexamethasone daily, group 2 are given 200 mg of IV hydrocortisone daily in 4 divided doses. Variables will be measured and recorded daily till patients get condition for discharge. Profiles and clinical examinations of patients as well as tests'll be performed by people who are blind to the groups.

Inclusion criteria: Patients hospitalized due to exacerbations of chronic obstructive pulmonary disease. Exclusion criteria: asthma, systemic corticosteroids use within the past month, recent myocardial infarction, acute irreversible heart failure, diagnosis of lobar pneumonia on Xray or lung CT scan

group1:the patients recieve 8mg IV dexametasone daily, In addition to standard treatment group2:the patients recieve 200mg IV hydrocortisone daily, In addition to standard treatment

General condition, Sputum level and density,Cough,Shortness of breath,Peak Expiratory Flow,Peripheral White Blood Cell Count,Acute Phase Reactive Protein,Malondialdehyde,Edema,Peripheral Blood Potassium,Systemic Blood Pressure,Sleep quality,Hospitalization Count,Arterial Blood Oxygen Saturation

The 70 patients in the study are randomly divided into two groups of 35 with a one-to-one ratio by complete random generation method. For this purpose, first the list of patients' names is prepared and numbered from 1 to 70, then patients with odd numbers will be assigned to group one and patients with even numbers will be assigned to group two.

Patients are explained that glucocorticoid drugs are standard treatment and there are no evidences to show one of them to be more effective than other in current condition. In this way, although patients do not know the name of their glucocorticoid drug, they will be aware of the general class of drugs and their side effects. Specifications and examinations will be recorded by a person who is blind to the groups and tests will be recorded by a person who is blind to the groups.

Individual data of participants will not be published. Published data can be shared after unidentifiable study subjects.

Start access since December 2021

Health researchers as well as reputable pharmaceutical companies

Health researchers and pharmacy researchers will be able to request information for this study by providing identification documents.

Gmail: a.hoseyni80@gmail.com Phone: +989177046952

-Submitting a formal request via e-mail Provide provable proof of authentication Provide the possibility of contacting the relevant university or industrial center Verification by us This process takes a maximum of two weeks.